Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta‐analysis
Appendices
Appendix 1. Cochrane Central Register of Controlled Trials search strategy
ID Search
#1 MeSH descriptor: [Prostatic Neoplasms] explode all trees
#2 (prostat* near/3 (cancer* or carcinoma* or malignan* or tumor* or tumour* or neoplas* or intraepithelial* or adenocarcinoma*))
#3 MeSH descriptor: [Prostatitis] explode all trees
#4 (prostatitis or prostatitides or prostatosis)
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Diphosphonates] explode all trees
#7 (diphosphonate* or diphosph*nate*)
#8 (bisphosph*nate* or biphosph*nate*)
#9 #6 or #7 or #8
#10 MeSH descriptor: [Alendronate] explode all trees
#11 (alendronat* or aledronic*)
#12 (fosamax* or binosto* or adronat* or alendros* or onclast*)
#13 #10 or #11 or #12
#14 MeSH descriptor: [Clodronic Acid] explode all trees
#15 (clodronic* or clodronat*)
#16 (bonefos* or clasteon* or difosfonal* or ossiten* or mebonat* or loron* or ostac*)
#17 Cl2MDP
#18 #14 or #15 or #16 or #17
#19 MeSH descriptor: [Etidronic Acid] explode all trees
#20 (etidronic* or etidronat*)
#21 (didronel* or xidifon* or dicalcium or xidiphon*)
#22 (HEDP or EHDP)
#23 #19 or #20 or #21 or #22
#24 MeSH descriptor: [Technetium Tc 99m Medronate] explode all trees
#25 (medronat* or medronic*)
#26 (Technetium near/2 Tc 99m near/2 Medronat*)
#27 #24 or #25 or #26
#28 (pamidronat* or pamidronic* or amidronat*)
#29 (aredia* or ADP sodium* or aminomux*)
#30 (GCP23339A or GCP‐23339A or YM529 or YM‐529)
#31 #28 or #29 or #30
#32 (zoledronic* or zoledronat*)
#33 (zometa* or zomera* or aclasta* or reclast* or aredia* or zoldron*)
#34 (m05BA08 or CGP‐42446* or CGP42446* or zol‐446 or zol446)
#35 #32 or #33 or #34
#36 (ibandronic* or ibandrovic* or ibandronat*)
#37 (bon*iva* or bondronat* or bondranat* or adronil*)
#38 (RPR102289A or RPR‐102289A)
#39 (BM210955 or BM‐210955)
#40 #36 or #37 or #38 or #39
#41 (risedronic* or risedronat*)
#42 (actonel* or atelvia* or benet*)
#43 (NE58095 or NE‐58095)
#44 #41 or #42 or #43
#45 (neridronat* or neridronic*)
#46 (AHHexBP or 6AHHDP or 6‐AHHDP)
#47 #45 or #46
#48 MeSH descriptor: [RANK Ligand] explode all trees
#49 (rank near/3 ligand*)
#50 RANK ligand inhibitor*
#51 (protein* near/2 (RANKL or TRANCE))
#52 Tumor Necrosis Factor‐Related Activation‐Induced Cytokin*
#53 #48 or #49 or #50 or #51 or #52
#54 MeSH descriptor: [Denosumab] explode all trees
#55 denosumab*
#56 (xgeva* or prolia*)
#57 (AMG162 or AMG‐162)
#58 #55 or #56 or #57
#59 tiludronat* or tiludronic* or skelid*
#60 Incadronat* or YM175 or YM‐175
#61 olpadronat* or olpadronic*
#62 #9 or #13 or #18 or #23 or #27 or #31 or #35 or #40 or #44 or #47 or #53 or #58 or #59 or #60 or #61
#63 #5 and #62 in Trials
Appendix 2. MEDLINE search strategy
| # | Searches |
| 1 | exp PROSTATIC NEOPLASMS/ |
| 2 | (prostat$ adj3 (cancer$ or carcinoma$ or malignan$ or tumo?r$ or neoplas$ or intraepithelial or adenocarcinoma$)).tw. |
| 3 | (prostat$ adj6 (cancer$ or carcinoma$ or tumo?r$ or neoplas$ or adenocarcinoma$)).ab,ti. |
| 4 | PROSTATITIS/ or prostatitis.tw. or prostatitides.tw. or prostatosis.tw. |
| 5 | or/1‐4 |
| 6 | exp DIPHOSPHONATES/ |
| 7 | (diphosphonate$ or diphosph#nate$).tw,kf,ot,nm. |
| 8 | (bisphosph#nate$ or biphosph#nate$).tw,kf,ot,nm. |
| 9 | or/6‐8 |
| 10 | ALENDRONATE/ |
| 11 | (alendronat$ or aledronic$).tw,kf,ot,nm. |
| 12 | (fosamax$ or binosto$ or adronat$ or alendros$ or onclast$).tw,kf,ot,nm. |
| 13 | or/10‐12 |
| 14 | CLODRONIC ACID/ |
| 15 | (clodronic$ or clodronat$).tw,kf,ot,nm. |
| 16 | (bonefos$ or clasteon$ or difosfonal$ or ossiten$ or mebonat$ or loron$ or ostac$).tw,kf,ot,nm. |
| 17 | Cl2MDP.tw,kf,ot,nm. |
| 18 | or/14‐17 |
| 19 | ETIDRONIC ACID/ |
| 20 | (etidronic$ or etidronat$).tw,kf,ot,nm. |
| 21 | (didronel$ or xidifon$ or dicalcium$ or didrocal$ or xidiphon$).tw,kf,ot. |
| 22 | (HEDP or EHDP).tw,kf,ot. |
| 23 | or/19‐22 |
| 24 | TECHNETIUM TC 99M MEDRONATE/ |
| 25 | (medronat$ or medronic$).tw,kf,ot,nm. |
| 26 | (Technetium adj2 Tc 99m adj2 Medronat$).tw,kf,ot,nm. |
| 27 | or/24‐26 |
| 28 | (pamidronat$ or pamidronic$ or amidronat$).tw,kf,ot,nm. |
| 29 | (aredia$ or ADP sodium$ or incadron$ or aminomux$).tw,kf,ot,nm. |
| 30 | (GCP23339A or GCP‐23339A or YM529 or YM‐529).tw,kf,ot,nm. |
| 31 | or/28‐30 |
| 32 | (zoledronic$ or zoledronat$).tw,kf,ot,nm. |
| 33 | (zometa$ or zomera$ or aclasta$ or zoldron$ or reclast$ or aredia$).tw,kf,ot,nm. |
| 34 | (m05BA08 or CGP‐42446$ or CGP42446$ or zol‐446 or zol446).tw,kf,ot,nm. |
| 35 | or/32‐34 |
| 36 | (ibandronic$ or ibandrovic$ or ibandronat$).tw,kf,ot,nm. |
| 37 | (bon?iva$ or bondronat$ or bondranat$ or adronil$).tw,kf,ot,nm. |
| 38 | (RPR102289A or RPR‐102289A).tw,kf,ot,nm. |
| 39 | (BM210955 or BM‐210955).tw,kf,ot,nm. |
| 40 | or/36‐39 |
| 41 | (risedronic$ or risedronat$).tw,kf,ot,nm. |
| 42 | (actonel$ or atelvia$ or benet$).tw,kf,ot,nm. |
| 43 | (NE58095 or NE‐58095).tw,kf,ot,nm. |
| 44 | or/41‐43 |
| 45 | (neridronat$ or neridronic$).tw,kf,ot,nm. |
| 46 | (AHHexBP or 6AHHDP or 6‐AHHDP).tw,kf,ot,nm. |
| 47 | or/45‐46 |
| 48 | RANK Ligand/ |
| 49 | (rank$ adj3 ligand$).tw,kf,ot,nm. |
| 50 | RANK ligand inhibitor$.tw,kf,ot,nm. |
| 51 | (protein$ adj2 (RANKL or TRANCE)).tw,kf,ot,nm. |
| 52 | Tumor Necrosis Factor‐Related Activation‐Induced Cytokin$.tw,kf,ot,nm. |
| 53 | or/48‐51 |
| 54 | DENOSUMAB/ |
| 55 | denosumab$.tw,kf,ot,nm. |
| 56 | (xgeva$ or prolia$).tw,kf,ot,nm. |
| 57 | (AMG162 or AMG‐162).tw,kf,ot,nm. |
| 58 | or/54‐57 |
| 59 | (tiludronat$ or tiludronic$ or skelid$).tw,kf,ot,nm. |
| 60 | (Incadronat$ or YM175 or YM‐175).tw,kf,ot,nm. |
| 61 | (olpadronat$ or olpadronic$).tw,kf,ot,nm. |
| 62 | 9 or 13 or 18 or 23 or 27 or 31 or 35 or 40 or 44 or 47 or 53 or 58 or 59 or 60 or 61 |
| 63 | 5 and 62 |
| 64 | randomized controlled trial.pt. |
| 65 | controlled clinical trial.pt. |
| 66 | randomi?ed.ab. |
| 67 | placebo.ab. |
| 68 | drug therapy.fs. |
| 69 | randomly.ab. |
| 70 | trial.ab. |
| 71 | groups.ab. |
| 72 | or/64‐71 |
| 73 | exp animals/ not humans/ |
| 74 | 72 not 73 |
| 75 | 63 and 74 |
Direct and indirect comparisons of interventions (strength of line represents number of trials evaluating the comparison; dotted lines are indirect comparisons).
